BCR and B-cell chronic lymphocytic leukemia: For example, in chronic lymphocytic leukemia (CLL) TP53 defects significantly reduce the efficacy of chemoimmunotherapy regimens functioning in other patients [2], and remain also challenging for innovative small-molecule inhibitors of B-cell receptor (BcR) signaling [3].